Objective. Congenital cardiac defects represent the most common group of birth defects, affecting an estimated six per 1000 births. Genetic characterization of patients and families with cardiac defects has identified a number of genes required for heart development. Yet, despite the rapid pace of these advances, mutations affecting known genes still account for only a small fraction of congenital heart defects suggesting that many more genes and developmental mechanisms remain to be identified. Design. In this study, we reviewed 1694 described cases of patients with cardiac defects who were determined to have a significant chromosomal imbalance (a deletion or duplication). The cases were collected from publicly available databases (DECIPHER, ISCA, and CHDWiki) and from recent publications. An additional 68 nonredundant cases were included from the University of Michigan. Cases with multiple chromosomal or whole chromosome defects (trisomy 13, 18, 21) were excluded, and cases with overlapping deletions and/or insertions were grouped to identify regions potentially involved in heart development. Results. Seventy-nine chromosomal regions were identified in which 5 or more patients had overlapping imbalances. Regions of overlap were used to determine minimal critical domains most likely to contain genes or regulatory elements involved in heart development. This approach was used to refine the critical regions responsible for cardiac defects associated with chromosomal imbalances involving 1q24.2, 2q31.1, 15q26.3, and 22q11.2. Conclusions. The pattern of chromosomal imbalances in patients with congenital cardiac defects suggests that many loci may be involved in normal heart development, some with very strong and direct effects and others with less direct effects. Chromosomal duplication/deletion mapping will provide an important roadmap for genome-wide sequencing and genetic mapping strategies to identify novel genes critical for heart development.
patient outcomes, recent studies suggest morbidity and mortality remains high for some of the most severe defects and that further improvements in outcomes may depend on the development of new therapeutic approaches. 1, 2 However, our ability to reduce the incidence or severity of heart defects is limited by an incomplete understanding of their causes. 3 Previous studies have identified genes responsible for some types of congenital heart defects (CHDs). 4, 5 To date, the identified genes appear to account for only a small percentage of the observed cases. This suggests that the pathophysiology of congenital heart disease is quite complex, potentially involving a large number of genes and genetic defects with variable levels of expressivity. Similar to other disorders demonstrating a complex pattern of inheritance, CHDs may often depend on the concurrent inheritance of multiple predisposing genetic factors that interact with epigenetic or environmental influences to result in impaired structural development. 6 The current challenge therefore is to identify such predisposing genetic factors that contribute to heart defects to aid development of new therapeutic strategies.
To meet this challenge, a number of approaches have been used to identify genes responsible for cardiac defects. In addition to the characterization of rare families with clear patterns of inheritance, targeted sequencing of genes determined to be potentially involved in heart development, either based on functional analysis in animal models or mapping chromosomal deletions/duplications in patients, has been successful in identifying causative mutations in patients with CHD. 3 In patients without significant chromosomal imbalances or clear familial inheritance, whole exome sequencing strategies have been utilized to identify disease-causing mutations in known or novel heart development genes. 7 Unfortunately, these nondirected sequencing strategies identify hundreds of novel genetic variants of unknown significance for each patient. Prioritizing sequence variants for further evaluation depends on (1) the identification of potentially pathogenic mutations using bioinformatics; (2) the identification and characterization of genes expressed in the tissues that contribute to cardiac development; and (3) the characterization of genetic and genomic abnormalities in other patients with congenital cardiac defects.
In this study, we sought to develop a roadmap for the prioritization of novel genetic variants in patients with heart defects by identifying genomic regions associated with congenital heart disease based on the mapping of chromosomal imbalances. Chromosomal imbalances occur approximately in 8-13% of patients with CHDs 8 and may represent important opportunities to localize and identify genes potentially involved in human cardiac development and the genesis of CHDs. In our review of publicly available databases and publications, we identified 1694 patients with a chromosomal imbalance (duplication or deletion) and congenital cardiac malformations. In addition, we identified 68 patients from our own institution. Patients with overlapping genomic abnormalities were grouped to identify minimal critical regions encompassing potential candidate genes involved in human cardiac development. We identified 79 chromosomal regions in which duplications or deletions have resulted in CHDs in five or more patients. Several of the regions identified have been noted previously to be involved in cardiac development including recurring deletions on chromosomes 7 and 22 (Williams and DiGeorge syndromes), and chromosomes 5 and 8 (involving the cardiac transcription factors NKX2-5 and GATA4). In addition, multiple sets of overlapping deletions and/or duplications were identified that may represent the locations of novel genes involved in cardiac development.
Methods

Database Search
The following three sources were used to identify patients for analysis: (1) the DECIPHER database (an international database containing genomic and phenotypic information on patients from over 150 centers in 29 countries) 9 ; (2) the International Standards for Cytogenomic Arrays (ISCA) consortium; and (3) the Benchv3.3 beta database. For each database, a series of search terms were used to identify cases involving CHDs. For the DECIPHER database, the search term "heart" was used to identify patients with CHDs. For the ISCA database, the following search terms were used: atrial septal defect (ASD), AV canal defect, coarctation of the aorta (CoA), hypoplastic left heart, tetralogy of Fallot (TOF), ventricular septal defect (VSD), and heart. The Benchv3.3 database included a linked site for identified cases with CHDs (http:// homes.esat.kuleuven.be/∼bioiuser/chdwiki/index .php/CHD:Reports). 10 
Expansion of the Database Using Published Data
In addition, data were pooled from four recent publications examining the contribution of copy number variation to the pathogenesis of CHDs. [11] [12] [13] [14] The formats used for copy number variant (CNV) identification and verification are described in each publication. Only those cases in which a single or primary CNV could be identified were included in the database for this study. Cases with more than one CNV were included if the "secondary" CNVs were known to be common in the general population and were less than 100 kb in size. Patients with identical recorded phenotypes and identical genomic imbalances represented in multiple databases and/or publications were deemed to be the same patient and were recorded only once.
Mapping of CNVs
For each case, the deleted or duplicated intervals had been previously mapped to the human genome reference sequence using the NCBI36/ hg18 or GRCh37/hg19 genome builds. All sequences were converted to the numbering of the GRCh37/hg19 genome build using the LiftOver program (http://genome.ucsc.edu/cgi-bin/ hgLiftOver). For those sequences not successfully converted by the LiftOver program, approximate boundaries were determined using nearby genes and markers in the NCBI36/hg18 genome build and locating the corresponding markers/genes on the GRCh37/hg19 genome map. As those boundaries are less definite, they are represented in red in the composite database.
Grouping of Cases with Overlapping CNVs
There are many approaches to group the observed cases. The full database can be retrieved and resorted based on specific interests or scientific questions. We have presented one approach, but there are many alternatives. To identify regions of overlap, the cases were sorted by chromosome and then sequentially by proximal and distal boundary location (using the GRCh37/hg19 genome build). Eighty-one regions with at least five cases of overlapping duplications and/or deletions were identified by visual inspection. Proximal and distal "secondary" boundaries were determined based on the presence of at least one case with a breakpoint internal to the proposed boundary. This was done to ensure that an important candidate gene would not be excluded based on a single breakpoint in an individual case. The candidate region was identified using the UCSC Genome Browser on Human Feb. 2009 (GRCh37/ hg19) Assembly (http://genome.ucsc.edu/cgi-bin/ hgGateway?hgsid=353279827). A list of genes in the region was recorded and examined for candidate genes known or suspected to have a role in human heart development. If a definite candidate was present, it was used to organize the overlapping cases in that all cases involving that locus were grouped prior to grouping the cases near but not involving the known cardiac gene. After regrouping based on candidate genes, a total of 79 candidate regions affected in five or more patients were identified.
Estimate of Percentage of Chromosomal Imbalances Associated with Congenital Cardiac Defects
For each of the 79 regions affected (included in a deletion or duplication) in five or more CHD patients, a candidate gene within the minimal region was identified and used to determine the copy number of that candidate region (recognizing that the selected gene may or may not be the one responsible for the observed cardiac defects). To determine if the incidence of cardiac defects associated with the gain or loss of that locus was in excess of what would be expected from a normal control population, we compared the rate of gain or loss of each locus in a population of patients referred to Signature Genomics for microarray testing with a diagnosis of a known cardiac defects (n = 1964) and in a control population without known heart disease (n = 8329). The analysis was restricted to this dataset as the other datasets were more subject to ascertainment bias making an accurate estimate of the denominator less reliable. The examined cases are a subset of the prenatal and postnatal cases submitted to Signature Genomics for clinical microarray-based comparative genomic hybridization from 2004 to 2013 (n = 58 980) and were tested using a variety of platforms, including targeted and whole-genome bacterial artificial chromosome arrays and wholegenome oligonucleotide-based arrays. This dataset includes all cases described in Cooper et al. 13 For each candidate region, the percentage of deletions and duplications that were associated with a reported cardiac defect was recorded. To determine if the observed difference between the CHD and control populations were statistically significant, a Wilcoxon signed rank test was used.
ratories at the University of Michigan using two oligonucleotide-based array platforms with whole genome coverage: a custom-designed EMArray Cyto6000 chip (Emory Genetics Laboratory, Decatur, GA, USA), implemented on the Agilent 44 K platform (Agilent Technologies, Inc., Santa Clara, CA, USA), 15 and the Illumina CytoSNP12 array. The procedures for array comparative genomic hybridization were performed according to the manufacturer's protocols as described in Quinonez et al. 16 The HumanCytoSNP-12 BeadChip assay (Illumina, San Diego, CA, USA), which targets the entire genome using 300 K probes, was performed according to the Infinium HD Ultra protocol provided by the manufacturer (Illumina). Briefly, 200 ng of genomic DNA was used for whole-genome amplification at 37°C for 20-24 hours. The amplified DNA was enzymatically fragmented, purified, loaded on the HumanCytoSNP-12 BeadChip, and allowed to hybridize at 48°C for 16-24 hours. Subsequently, the hybridizing DNA on the BeadChip was labeled by enzymatic single base extension and incorporated nucleotides were detected using fluorescently labeled antibodies. Stained BeadChips were scanned using a HiScan (Illumina). Data were generated with GenomeStudio (Illumina) and analyzed with Nexus Copy Number software version 6 (BioDiscovery, Hawthorne, CA, USA).
Results
The 1694 patients with congenital cardiac defects and chromosomal imbalances were identified in the databases and publications examined in this study, and 68 patients with congenital cardiac defects and chromosomal imbalances were included from our institution. The deletion or duplication was assigned to a specific chromosomal segment based on the available mapping data. The set of genes affected by the chromosomal imbalances were retrieved from the databases and used to develop a minimum overlapping set of genes for each locus. We identified 79 potential genetic loci that were involved in a minimum of five overlapping deletions or duplications (see Table 1 and Supporting Information Table S1 ).
Distribution of Insertions/Deletions Leading to CHDs
Chromosomal deletions and duplications associated with CHDs were not randomly distributed throughout the genome. There was clustering of CHD-associated genomic imbalances at particular chromosomal locations, including those involved in known cardiac syndromes and at the telomeres. Telomeric and subtelomeric deletions and duplications associated with congenital cardiac defects involved regions on distal chromosomes 1p, 1q, 2q, 3p, 3q, 4p, 5p, 5q, 6p, 8p, 9p, 9q, 10q, 11p, 11q, 12p, 14q, 15q, 16p, 16q, 17p, 17q, 18q, 19p, and 20q.
Chromosomal Duplication/Deletions Affecting Loci Known to Have a Role in CHD
As would be expected, there were a number of patients with chromosomal imbalances affecting regions previously determined to have role in heart development. Deletions affecting TBX1 (DiGeorge syndrome) and elastin (Williams syndrome) were identified in 36 and 18 patients, respectively. These deletions may be relatively underrepresented in the databases as they have been well described and there is little incentive to catalogue additional patients with these deletions. Deletions affecting NKX2-5 and GATA4 were identified in 7 and 38 patients, respectively. Five of the patients with NKX2-5 deletions were described as having ASDs with or without other cardiac abnormalities including atrioventricular block in three patients. There was a broad range of defects in patients haplosufficient for GATA4 with the majority being described as atrial or ventricular septal defects and relatively frequently, in 12/38 patients, complete atrioventricular septal defects. This is consistent with a recent finding that copy number variants affecting GATA4 were overrepresented in patients with atrioventricular septal defect (AVSD). 12 Mutations in transforming growth factor-beta (TGFβ)-activated kinase (TAB2) have previously been noted in patients with CHDs. 17 Deletions of TAB2 were noted in 11 patients and a duplication in one patient with a range of cardiac defects including ASDs and VSDs, as well as aortic and pulmonary stenosis. Several other genes previously noted to have deleterious mutations in patients with CHDs were affected by chromosomal imbalances in at least five patients including CRELD1, CHD7, CREBBP, EHMT1, HAND2, and NOTCH1 (Table 1) .
Chromosomal Insertions/Deletions Affecting Loci Suspected to Have a Role in CHD
Other chromosomal imbalances involved loci that contain genes that have been demonstrated in animal models to be involved in heart develop-ment but have not previously been implicated in causing human CHDs. These included imbalances involving ETS1, HES4, MEF2A, MTHFR, TBX2, or TBX6 in five or more patients (Table 1) .
Relative Risk of Congenital Cardiac Defects for Each Candidate Region
One of the major limitations of relying on database reporting for this type of analysis is the inability to assess risk of developing a cardiovascular abnormality if a particular gene or genetic region is involved in a chromosomal imbalance. To address this, we reviewed a large dataset of patients tested at a clinical microarray laboratory (Signature Genomics Inc., Spokane, WA, USA), which includes those reported by Cooper et al. 13 From that dataset, a rough estimate could be obtained of the relative risk of a CHD when a specific gene was involved in a chromosomal imbalance by comparing the gain or loss of that gene in a population of patients with known or suspected cardiac defects referred for copy number analysis com- Shown are the chromosome (Chrom) and approximate genetic location (Genome Reference Consortium Human Build 37 [GRCh37/hg19]), a gene within the minimal region of overlap and the observed spectrum of heart defects. Genes that have been previously identified with coding sequence mutations in patients with congenital cardiac defects are in red text; those determined to have a role in heart development based on an animal model (but without identified sequence variants in patients with heart defects) are in blue. Each locus spans multiple genes, and the location and listed gene are only intended to provide a landmark for the candidate interval. The boundaries of the critical region can be derived from the individual cases presented in Supporting Information Table S1 . Heart defects listed include coarctation of the aorta (CoA), interrupted aortic arch (IAA), hypoplastic left heart syndrome (HLHS), atrial and ventricular septal defects (ASDs and VSDs), atrioventricular septal defect (AVSD), tetralogy of FALLOT (TOF), double outlet right ventricle (DORV), bicuspid aortic valve (BAV), truncus arteriosus (CAT), situs inversus (SI), heterotaxy (HET), supravalvar aortic and pulmonary stenosis (SVAS and SVPS), aortic stenosis or insufficiency (AS or AI), pulmonary stenosis or insufficiency (PS or PI), tricuspid stenosis or regurgitation (TS or TR), mitral stenosis or regurgitation (MS or MR), total or partial anomalous venous return (TAPVR or PAPVR), tricuspid atresia (TA), pulmonary atresia (PA), patent ductus arteriosus (PDA), left or bilateral superior vena cava (LSVC or BSVC), cardiomyopathy and left ventricular noncompaction (CM and LVNC), and Ebstein's anomaly (EBS). If the heart defect was not described, then "HEART" is listed.
pared with a healthy control population. This analysis was performed for the 79 loci noted to be involved in chromosomal copy number variations in at least five patients. For 66 of the 79 loci involved in chromosomal imbalances in five or more cases with CHD, the incidence of deletions and duplications in a control population of 8329 individuals without known CHDs was available. A total of 36 of these 66 loci were noted to have a significantly increased risk of CHDs compared with control when involved in a chromosomal duplication and/or deletion ( Table 2 ). As noted above, 11 of the loci (including loci containing the ELN, HAND2, GATA4, GJA5, and TBX1) demonstrated significant elevations in CHD risk when the locus was duplicated and when it was deleted while the remaining 25 only achieved significance for a duplication or a deletion. For many loci, there were not enough occurrences of a duplication or deletion to calculate a meaningful statistic for that type of imbalance. Given the rarity of chromosomal loss or gain in the healthy population, it was difficult to exclude any of the identified loci as definitively not being associated with an increased risk of CHD with a gain or a loss. However, frequent chromosomal imbalances of loci on chromosome 7q31.1 (which includes IMMPL2) and on chromosome 6q26 (which includes PARK2) in the control population makes their involvement in CHD pathogenesis unlikely. Furthermore, several loci were only reported from a single database raising the possibility that the assignment of a chromosomal imbalance was an artifact of the testing format. In fact, this single data source artifact might account for six of the 12 loci for which imbalances were noted in five or more CHD cases, but no incidence data were available. These loci are also unlikely to be involved in CHD pathogenesis.
Other genes previously implicated in CHD pathogenesis, including the NOTCH1, TAB2, and CHD7 genes, were more frequently involved in chromosomal imbalances in patients with CHD than in controls. In general, genes determined to be important for cardiac development were not commonly involved in chromosomal imbalances and when imbalances do occur they are commonly associated with congenital cardiac defects. Therefore, a complementary approach to assessing risk of CHD is to estimate penetrance of CHD in individuals with a gain or loss of a specific gene or locus ( Table 3) . Deletions of GATA4 were noted to be associated with congenital cardiac defects in 9/21 patients in the Signature dataset 13 and 11/11 patients in the DECIPHER database. Interestingly, deletions involving TBX1 resulted in reported cardiac abnormalities in 27% of the patients in the Signature dataset and in 40% of the patients in the DECIPHER database. This is comparable with the previously reported rate of cardiovascular abnormalities (approximately 25%) in patients with DiGeorge syndrome. 18 Chromosomal imbalances involving NOTCH1, which has been demonstrated to be responsible for cardiac defects in some families, 19 are also associated with an elevated risk of CHDs. The incidence of reported cardiac defects in patients with deletions of NOTCH1 is approximately 50% based on the datasets from DECI-PHER and from the Signature database. 13 Therefore, the frequency with which a chromosomal deletion involving a gene known to be involved in heart development results in a congenital cardiac defect varies and the penetrance is usually incomplete suggesting that other factors, either genetic or environmental, may be important for chromosomal imbalances to cause clinically significant congenital heart disease.
Refinement of Candidate Loci for CHD
How the data in the databases can be used to restrict the candidate regions for novel genes involved in human heart development and the pathogenesis of CHD is demonstrated with the following examples. All cases in the signature dataset and DECIPHER databases that involved the candidate gene were examined; shown are the number of cases with reported congenital cardiac defects over the total number of cases. Color coding of genes is as described for Table 1 . Note that, even for genes such as TBX1 that have been clearly linked to congenital heart defects, chromosomal imbalances involving those genes result in clinically recognized cardiac defects in only a subset of cases. Locus at 1q24.2
In the databases, we identified seven individuals with deletions involving 1q24.2. The heart defects were variable but included VSD (3 patients), patent foramen ovale (PFO; 2 patients), heart defect not otherwise specified (1 patient) and ECG abnormality (1 patient) (Table 4A) . We identified a primary critical region (CR), where the proximal and distal boundaries were each determined by a single case, that included nine genes. A secondary CR, defined by allowing the exclusion of single cases, included additional genes. None of the genes within the primary and secondary CRs has a known role in heart development or the pathogenesis of congenital cardiac defects. Although a risk calculation could not be performed using a gene (PRRX1) within the primary CR, the absence of chromosomal imbalances involving this region in healthy controls supports its potential role in CHD pathogenesis.
Locus at 2q31.1
Fourteen individuals with deletions (12 patients) or duplications (2 patients) involving 2q31.1 were identified (Table 4B ). The heart defects were primarily septal defects including VSD 6 and ASD. 3 The primary CR contained six genes with a secondary CR containing another 2. Within the primary CR is the gene encoding for CIR1 that has been reported to regulate the Notch signaling pathway and to be abundantly expressed in the heart 20 and the gene encoding for the SP3 transcription factor, which has been demonstrated in a mouse model to have an important role in heart development. 21 There was one case (Wiki389) in which the deletion did not significantly overlap with two other deletions in the region suggesting that (1) there is another cardiac gene located more proximally on chromosome 2, (2) there is an effect of the deletion on nearby genes, or (3) the deletion, in that case, is not directly responsible for the observed cardiac defect. Although a risk calculation could not be performed using a gene (CIR1) within the primary CR, the absence of chromosomal imbalances involving this region in healthy controls again supports its potential role in CHD pathogenesis.
Locus at 15q26.3
Thirteen individuals with deletions (9 patients) or duplications (4 patients) involving 15q26.3 were identified (Table 4C) . A broad range of cardiac defects were noted but some less common heart defects appeared to be overrepresented including hypoplastic left heart syndrome (HLHS) in 3.
CoA and ventricular septal defects were also relatively common. Of the genes in the primary and secondary CRs, the gene encoding the MEF2A transcription factor is an important candidate based on its high level of expression in the developing heart in animal models. 22 
DiGeorge Syndrome Region
Previous studies have noted that mutation affecting TBX1 in human patients 23 or the targeted depletion of Tbx1 in animal models [24] [25] [26] can reproduce many of the cardiac manifestations of DiGeorge syndrome including the development of conotruncal-type CHDs. However, it has also been noted that chromosomal imbalances involving chromosome 22q11 but not including TBX1 can also be associated with heart defects. 27, 28 Therefore, we examined the cases within the databases to determine if there was evidence that multiple genes on chromosome 22q11 might be involved in cardiac defects. We identified 85 chromosomal imbalances involving chromosome 22q11 in the database. Seventy-eight of the 85 involved at least one of three genes, TBX1, CRKL, and MAPK1, previously determined or suspected to have a role in human heart development and in the pathogenesis of CHDs. Of these, seven involved chromosomal imbalance of TBX1 alone, 35 involved TBX1 and CRKL, eight involved CRKL alone, four involved both CRKL and MAPK1, and 19 involved MAPK1 alone (Table 5) . Small (<300 kb) chromosomal imbalances involving chromosome 22q11 distal to MAPK1 were noted in six patients from one database, but these may reflect nonpathogenic rearrangements or uncertain CNV ascertainment based on a single testing format.
Discussion
General Approach
Identification of the causes of CHDs has proved to be a challenging task. The underlying genetic abnormality responsible for a cardiac defect is known in only a very small minority of patients. Characterization of patients with chromosomal imbalances and associated congenital cardiac abnormalities is an attractive approach to identifying disease genes that has been successful in identifying ELN (elastin), TBX1 and GATA4 as genes involved in the pathogenesis of congenital cardiac defects. Unfortunately, there are currently a number of obstacles to this approach. Perhaps, most importantly is the lack of a centralized, I  nssv579955  VSD  22  DEL  hg19  17019015  20718227  TBX1  I  nssv575290  HEART  22  DEL  hg19  18706001  20659606  TBX1  I  nssv575290  VSD  22  DEL  hg19  18890271  20659606  TBX1  W  1412  VSD  22  DEL  hg19  18894835  20659606  TBX1  C  9908014  HEART  22  DEL  hg19  18986906  20246906  TBX1  I  nssv577056  HEART  22  DEL  hg19  19771355  21123068  TBX1  I  nssv579962  CoA  22  DUP  hg19  19074579  19928090  TBX1  I  nssv1603215  HEART  22  DEL  hg19  18660553  21455556  TBX1/CRKL  I  nssv579970  VSD  22  DEL  hg19  18661724  21561514  TBX1/CRKL  I  nssv579984  HEART  22  DEL  hg19  18661724  21561514  TBX1/ I  nssv579999  TOF  22  DEL  hg19  18919942  21440514  TBX1/CRKL  C  9906174  HEART  22  DEL  hg19  18919942  21440514  TBX1/CRKL  C  9892257  CoA  22  DEL  hg19  18919942  21440514  TBX1/CRKL  I  nssv582251  ASD  22  DEL  hg19  18919942  21505417  TBX1/CRKL  I  nssv576304  VSD  22  DEL  hg19  18919942  21505417  TBX1/CRKL  I  nssv580013  HEART  22  DEL  hg19  18919942  21505417  TBX1/CRKL  I  nssv580012  HEART  22  DEL  hg19  18919942  21505417  TBX1/CRKL  I  nssv580007  CHF  22  DEL  hg19  18919942  21505417  TBX1/CRKL  I  nssv575367  ASD  22  DEL  hg19  18919942  21561514  TBX1/CRKL  I  nssv580006  HEART  22  DEL  hg19  18938161  21455556  TBX1/CRKL  I  nssv583020  HEART  22  DEL  hg19  18938161  21455556  TBX1/CRKL  I  nssv580004  PS  22  DEL  hg19  18938161  21455556  TBX1/CRKL  I  nssv582339  VSD  22  DEL  hg19  19023824  21798755  TBX1/CRKL  I  nssv580045  SAS  22  DUP  hg19  18627818  21940122  TBX1/CRKL  I  nssv580051  AVSD  22  DUP  hg19  18660553  21455556  TBX1/CRKL  I  nssv580052  HEART  22  DUP  hg19  18781534  21465835  TBX1/CRKL  C  9893158  HEART  22  DUP  hg19  18919942  21801604  TBX1/CRKL  D  1640  AVSD  22  DUP  hg19  19573160  21461017  TBX1/CRKL  D  251689  TOF  22  DEL  hg19  20330744  21465481  CRKL  D  254167  AAo  22  DEL  hg19  20659547  21561514  CRKL  TM  9  HEART  22  DEL  hg19  20733427  21505417  CRKL  D  768  ASD; PDA  22  DEL  hg19  20734244  21460658  CRKL  D  986  VSD  22  DEL  hg19  20743536  21462353  CRKL  TM  25  VSD  22  DEL  hg19  20754422  21440514  CRKL  D  262483  SAS  22  DUP  hg19  20763207  21461765  CRKL  I  nssv580061  TOF  22  DUP  hg19  20769981  21037727  CRKL  I  nssv580065  VSD  22  DEL  hg19  20372210  22548710  CRKL/MAPK1  W  1488  CAT  22  DEL  hg19  20976969  22484320  CRKL/MAPK1  S  B00BEJC  ASD  22  DEL  hg19  21075575  22467350  CRKL/MAPK1  I  nssv575749  HEART  22  DUP  hg19  21025653  22467351  CRKL/MAPK1  TM  21  CAT  22  DEL  hg19  21692108  23575642  MAPK1  S  B00B1CM  AVSD  22  DEL  hg19  21721591  22970128  MAPK1  W  98  AVSD  22  DEL  hg19  21721591  22970128  MAPK1  C  9895786  VSD  22  DEL  hg19  21798104  23739485  MAPK1  D  2366  HEART  22  DEL  hg19  21799773  23654237  MAPK1  S  B00BE7D  HEART  22  DEL  hg19  21808750  24643264  MAPK1  D  251833  HEART  22  DEL  hg19  21811979  24616199  MAPK1  D  251833  AI  22  DEL  hg19  21939922  24643109  MAPK1  D  250255  VSD; ASD; PDA  22  DEL  hg19  22095272  22834113  MAPK1  D  248709  CAT  22  DEL  hg19  22095272  22834113  MAPK1  I  nssv580074  CAT  22  DEL  hg19  22095272  22834113  MAPK1  I  nssv580080  CAT  22  DEL  hg19  22095272  22834113  MAPK1  TM  29  VSD; RAO  22  DEL  hg19  22095272  22834113  MAPK1 searchable, and well-annotated database of wellphenotyped patients with clearly defined chromosomal imbalances. The obstacles to achieving this goal are not insurmountable and would yield enormous benefits for all patients with developmental defects, including heart defects. Although there are very important limitations to the databases in their current state that restrict the ability to make conclusions based on these data, the database review suggested several important considerations with regard to human heart development and the pathogenesis of human congenital cardiac defects. Most importantly, the database review reinforces the observation that haploinsufficiency or duplication of even genes known to be critical for heart development only results in heart defects in a subset of cases. For instance, haploinsufficiency of TBX1 led to clinically significant heart defects in 27% of patients in the Signature dataset and 40% in the DECIPHER database. The Signature dataset may have a lower ascertainment and reporting bias but also may under-report or under-detect heart defects. The DECIPHER database is more prone to ascertainment and reporting bias, which may inflate the estimated frequency of heart defects in patients with 22q11 deletions. Clearly, other factors are involved that help determine whether an individual with a genetic predisposition, such as TBX1 haploinsufficiency, manifests a significant cardiac abnormality.
At least some of the clinical variability in cases of chromosome 22q11 deletion may be related to the extent of the deletion. In the database, as has been noted in previous studies, most commonly, cases (30 out of 85 reported) with a CHD and a chromosomal imbalance affecting chromosome 22q11 had an approximately 3 Mb deletion, which included both the TBX1 and CRKL genes. A smaller 1.5 Mb deletion involving TBX1 but not CRKL was noted in six patients in the database. The smaller deletion has been previously noted to account for DiGeorge syndrome in approximately 7% of cases and the larger deletion in 88%. 29, 30 The smaller deletion has been noted to be sufficient to produce the full DiGeorge syndrome phenotype 31 including conotruncal heart defects, 32 but there has been noted to be an important difference in the rate at which the 1.5 Mb deletion and the 3 Mb deletion are passed to offspring. 33 The reduced rate of transmission of the larger deletion may indicate that the early developmental defects are more penetrant or more severe in the patients with the larger deletion. In our database, the patients with the smaller 1.5 Mb deletion had ventricular septal defects and unspecified heart abnormalities while those with the larger 3 Mb deletion, encompassing both TBX1 and CRKL, demonstrated a range of heart defects including TOF (six cases), VSD (three cases), and pulmonary stenosis (one case). Conotruncal heart defects including truncus arteriosus (CAT) and TOF were Data presented for each case includes the database source, the case ID number, the type of heart defect noted (CHD), the chromosome affected by the deletion or duplication (Chrom), the type of chromosomal imbalance (deletion [DEL] or duplication [DUP]) identification, the genome build of the annotated sequence involved (all hg19), and the approximate proximal (Boundary 1) and distal (Boundary 2) boundaries of the observed imbalance, and the candidate gene or genes involved in the imbalance (Locus). The chromosomal imbalances were divided into those involving just TBX1, TBX1 and CRKL, CRKL only, CRKL and MAPK1, MAPK1 only, and all three. Shading indicates involvement of more that one candidate gene. In six cases, a small chromosomal rearrangement occurred between CRKL and MAPK1 but did not involve either gene. All of those cases did involve imbalance of the gene TOP3B, a gene not known to be involved in heart development. Only one chromosomal imbalance of 22q11 did not involve one of those four loci. Nomenclature for heart defects is the same as for Table 1 . Sources listed include the following databases and publications: Cooper et al. 13 (C), DECIPHER (D), ISCA (I), CHDWiki (W), Tomita-Mitchell et al. 12 (TM), Greenway et al.
11
(G), Soemedi et al. 14 
(S), and the University of Michigan (M).
Congenit Heart Dis. 2015; 10:193-208 noted in cases involving deletions distal to the 1.5 Mb smaller DiGeorge syndrome deletion, including deletions involving (1) the distal part of the 3 Mb deletion region (and including CRKL) and/or (2) deletion of more distal 22q11 including MAPK1. The ability of 22q11 deletions that do not involve TBX1 to result in conotruncal cardiac defects has been previously noted in cases involving the loss of both CRKL and MAPK1. 28 Therefore, the concurrent loss of 2 or more genes involved in cardiac development as occurs with the simultaneous loss of TBX1 and CRKL in the larger and more common 3 Mb DiGeorge syndrome deletion or with the less common simultaneous loss of CRKL and MAPK1 may enhance the penetrance of cardiac defects in patients with 22q11 deletions. This is supported by knockout studies in mice that demonstrated a higher penetrance and severity of cardiac defects in mice haplosufficient for both TBX1 and CRKL compared to mice haplosufficient for either individually. 34 CHD penetrance may also vary by disease locus. Chromosomal imbalances involving GATA4 and NKX2-5 are rare but, when they occur, seem to be associated with a high frequency of clinically significant cardiac defects. Few other loci appear to have comparable penetrance with regard to haploinsufficiency and the incidence of heart defects. However, disease genes that reside in regions that are relatively stable (i.e., very rarely involved in chromosomal imbalances) or in regions where chromosomal imbalances are associated with markedly reduced viability may be difficult to detect using this approach.
The generated composite database of each individual case (Supporting Information Table S1 ) will provide a useful starting point for the identification of novel genomic regions potentially involved in human heart development and the pathogenesis of congenital cardiac defects. Identification of such regions will facilitate the interpretation of genome-wide sequencing data, in the search for the genetic determinants of congenital cardiac defects. As cases are added to the database there may be further refinement of the region determined to be critical for heart development. Examples of how deletion/duplication mapping may be used to restrict candidate regions and identify potential candidate genes are described below.
Locus at 1q24.2
Deletions of 1q24 are relatively uncommon. There was a report of seven patients with deletion of 1q24.3-1q25 that overlaps minimally with the CHD CR defined in this study. 35 Cardiac defects were not noted to be an important feature of their observed phenotype. As noted above, none of the genes within the primary and secondary CRs has a known role in heart development or the pathogenesis of congenital cardiac defects. Of the genes in the primary CR, GORAB, and PRRX1 are expressed in the heart, but loss of function in human patients or in animal models is not associated with heart defects. [36] [37] [38] Similarly, in the secondary CR, VAMP4, and DNM3 are expressed the heart, but no role in cardiac development has been identified. In addition, there are a number of miRNAs that have been identified within the CRs at this locus. Most interesting is mir-214, which is encoded within the DNM3 locus, is highly expressed in the heart and promotes myogenic differentiation. 39 Locus at 2q31.1 Duplication of chromosome 2q31.1 has been noted in a 3 generation family with mesomelic dysplasia, 40 but deletions involving 2q31.1 are relatively uncommon. 41 The predominant cardiac lesions in patients with 2q31.1 deletions that have been recorded in the databases are defects in cardiac septation resulting in ASDs and VSDs. Within the primary CR on chromosome 2q31 is CBF1-interacting co-repressor (CIR1) ( Table 4B) . CBF1 (or RBPJ) is a transcriptional repressor whose activity is de-repressed by binding to the Notch intracellular domain, making it a key target in Notch-mediated transcriptional activation. CIR1's high level of expression in the heart and interaction with a signaling pathway critical for heart development make CIR1 a likely candidate for the observed cardiac defects in these patients. 20 Other genes within the primary and secondary CRs that are expressed in the heart include PDK1 (pyruvate dehydrogenase kinase), transcription factor SP3, and ZAK. ZAK encodes a kinase that activates MAPK1, 42 another kinase implicated in the pathogenesis of congenital cardiac defects, 28 and SP3 encodes for a transcription factor that is required for normal heart development in the mouse. 21 
Locus at 15q26.3
A recurring deletion of chromosome 15q26.3 described by Rump et al. 43 was noted to be responsible for a distinct clinical phenotype that had been named Drayer syndrome. Common features include micrognathia, developmental delay, skeletal anomalies and growth failure. As noted above, MEF2A, a transcription factor strongly expressed in smooth muscle throughout the body, including the smooth muscle of the developing heart tube, is a strong candidate for the heart defects associated with 15q26 deletions as has been previously proposed. 44 Another candidate within the region is ADAMTS17, which is expressed in the developing heart. 45 However, deleterious mutations of ADAMTS17 in human patients cause ocular and ophthalmologic abnormalities but have not led to the development of CHDs. 45 It is important to note that haploinsufficiency of this region did lead to heart defects with related etiologies, as two of the more commonly noted lesions with these deletions, HLHS and CoA, can occur together in families and are often defined as closely related left-sided obstructive lesions. 46 Therefore, a gene or genes within this region may be an important candidate(s) to consider when evaluating patients with left-sided obstructive lesions including HLHS.
DiGeorge Region
In several regions, nonoverlapping chromosomal imbalances are associated with cardiac defects, suggesting that more than one gene in the region participates in heart development. Given that (1) the "penetrance" of the cardiac phenotype in response to a chromosomal imbalance is variable and can be quite low even for imbalances involving a gene known to participate in heart development and (2) the incidence of heart defects in the general population is high enough that not all defects can be assumed to be "caused" by the observed imbalance, it can be very difficult to determine the precise extent of the candidate regions and the number of heart development genes involved. One region that may contain more than a single gene involved in heart development is chromosome 22q11, which includes the DiGeorge syndrome CR. As noted above, TBX1, which encodes for a T-box cardiac transcription factor, is within the CR and has been demonstrated in animal models to have an important role in heart development. 23, 26, 47 However, nonoverlapping chromosomal imbalances associated with heart defects have suggested the possibility of two additional 22q11 genes involved in heart development, and several lines of evidence support the potential involvement of the CRKL and MAPK1 genes. 28, 48, 49 Review of the cases in the databases support the existence of at least three genes on chromosome 22q11 that contribute to cardiac development.
Limitations
As noted above, there are a number of important limitations to this study. The databases and publications included in this analysis do not share a common genotyping platform, do not have a consistent approach to phenotyping or phenotype reporting and are entirely voluntary. We have included a supplemental table that contains some basic information regarding each of the reported cases (Supporting Information  Table S1 ). We recognize that our list of 79 loci involved in five or more rearrangements is incomplete and that there will be many instances where (1) multiple candidate genes have been encompassed by a single locus; (2) only a single candidate gene is present where there are several closely spaced candidate regions; (3) "false" loci have been created by database errors, random chance and genomic instability; and (4) "true" loci have been missed due to genomic stability (leading to very few cases of chromosomal imbalance for evaluation) and/or reduced viability of affected embryos. The list is meant to be a preliminary effort to consolidate what is known to date and it will need to be refined or replaced as case reporting becomes more standardized. The supplementary table will serve as a platform for identifying new candidate loci as additional cases are added to the database and will help to further refine existing loci.
Summary
Despite the limitations of this study, the database analysis demonstrates the potential value of this approach to restrict regions of interest for genes involved in developmental disorders including congenital cardiac defects. The low penetrance for observable cardiac defects associated with most chromosomal imbalances, the infrequent occurrence of chromosomal abnormalities in most genomic regions, and the relatively common occurrence of some types of cardiac defects (such as ASDs and VSDs) in the general population will make it difficult to define CRs based on a single patient or small cohorts. Therefore, there will be tremendous value in establishing standardized processes for reporting observed chromosomal imbalances and associated clinical phenotypes. The refined map of loci involved in human cardiac development will be essential as genome-wide sequencing approaches become more prevalent in the search for the genetic determinants of congenital cardiac defects.
Congenit Heart Dis. 2015; 10:193-208 
